

Shalom Haggiag

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5062080/shalom-haggiag-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30
papers

308
citations

10
h-index

16
g-index

33
ext. papers

488
ext. citations

5
avg, IF

3.33
L-index

#	Paper	IF	Citations
30	Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies.. <i>Journal of Neurology</i> , 2022 , 1	5.5	4
29	Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies. <i>Neurology</i> , 2021 ,	6.5	23
28	Increased risk of death from COVID-19 in multiple sclerosis: A meta-analysis of observational studies. <i>Journal of the Neurological Sciences</i> , 2021 , 429, 117776	3.2	2
27	Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1391-1402	5	10
26	Ozone-induced encephalopathy: A novel iatrogenic entity. <i>European Journal of Neurology</i> , 2021 , 28, 2471-2478	1	
25	Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score. <i>European Journal of Neurology</i> , 2021 , 28, 2533-2542	6	3
24	Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy. <i>Journal of Neurology</i> , 2021 , 268, 2895-2899	5.5	2
23	Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	3
22	Monoallelic KIF1A-related disorders: a multicenter cross sectional study and systematic literature review. <i>Journal of Neurology</i> , 2021 , 1	5.5	3
21	Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies. <i>Journal of Neurology</i> , 2021 , 1	5.5	10
20	Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study. <i>Neurotherapeutics</i> , 2020 , 17, 994-1004	6.4	10
19	Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 271-277	5.5	9
18	Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study. <i>Journal of Neurology</i> , 2020 , 267, 694-702	5.5	2
17	Premorbid functional reserve modulates the effect of rehabilitation in multiple sclerosis. <i>Neurological Sciences</i> , 2020 , 41, 1251-1257	3.5	5
16	The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray). <i>PLoS ONE</i> , 2019 , 14, e0219670	3.7	2
15	Electrophysiological abnormalities in iatrogenic botulism: Two case reports and review of the literature. <i>Journal of Clinical Neuroscience</i> , 2019 , 60, 138-141	2.2	9
14	Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 1272-1278	5.5	6

13	Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case report. <i>Journal of Neurology</i> , 2018 , 265, 2152-2153	5.5	6
12	Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study. <i>CNS Drugs</i> , 2018 , 32, 963-970	6.7	25
11	Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study. <i>Neurology</i> , 2018 , 91, e153-e161	6.5	25
10	Impact of Māiāes Rehabilitative Method in Patients with Parkinson's Disease: A Randomized Controlled Trial. <i>Parkinson's Disease</i> , 2017 , 2017, 2762987	2.6	2
9	Discrepancies between urinary symptoms assessment and objective bladder dysfunctions in multiple sclerosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017 , 2,	0	2
8	Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis. <i>Journal of Neurology</i> , 2017 , 264, 284-294	5.5	33
7	Extratemporal herpes encephalitis during natalizumab treatment: A case report. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 10, 134-136	4	5
6	The "gender factor" in wearing-off among patients with Parkinson's disease: a post hoc analysis of DEEP study. <i>Scientific World Journal, The</i> , 2015 , 2015, 787451	2.2	38
5	Early-onset optic neuropathy as initial clinical presentation in SPG7. <i>Journal of Neurology</i> , 2014 , 261, 1820-1	5.5	11
4	Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 1243-53	5.9	8
3	Efficacy and safety of laquinimod in multiple sclerosis: current status. <i>Therapeutic Advances in Neurological Disorders</i> , 2013 , 6, 343-52	6.6	13
2	Painful and involuntary multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 763-77	4	9
1	Induction of neuronal and myelin-related gene expression by IL-6-receptor/IL-6: a study on embryonic dorsal root ganglia cells and isolated Schwann cells. <i>Experimental Neurology</i> , 2007 , 208, 285-96	5.7	25